|
| |
Interactive Case Study
|
 |
April 2007
1.25 AMA PRA Category 1 Credits™
Expiration date: April 30, 2008
- A 73-Year-Old Woman With Metastatic Non–Small-Cell Lung Cancer and Marginal Performance Status
|
|
 |
February 2007
1.5 AMA PRA Category 1 Credits™
Expiration date: February 29, 2008
- A 63-Year-Old Woman With Metastatic Non–Small-Cell Lung Cancer
|
|
| |
LECTURES
|
Current Trends in Lung and Head & Neck Cancers
March 7, 2008
Atlanta, GA
- Adjuvant Therapy for NSCLC: Where Are We in 2008?
- Combined-Modality Therapy for Stage III NSCLC
- State of the Art in Advanced NSCLC
- What’s New With Angiogenesis Inhibitors in NSCLC?
- Recent Developments With EGFR Inhibition
- Pharmacogenomic Customization of Lung Cancer Therapy
- Novel Agents in Development for NSCLC
- Head and Neck Cancer: Current Clinical Data in 2008
- 2008 Controversies in Head and Neck Cancer
|
|
Emerging Pathways With Therapeutic Potential in Cancer
June 1, 2007
Chicago, IL
- Targeting Signaling Pathways as a Core Strategy for Inhibiting Cancer Cell Growth
- Clinical Development of Agents Targeting the MAP/MEK and PI3K/Akt Pathways: Key Regulators of Proliferation and Survival in Cancer
- Novel Strategies to Inhibit Signaling Through VEGF Receptor in the Treatment of Cancer
- Targeted Immunotherapy for Lung Cancer
- Potential Immunologic Targets in Melanoma
- Combining Targeted Agents in Solid Tumors: Will Horizontal or Vertical Inhibition Improve the Therapeutic Index in Cancer?
|
|
Translating the Complexities of Cancer Development Into Novel Therapeutics
June 1, 2007
Chicago, IL
- Dual Inhibition of EGFR and VEGF Signal Transduction as a Therapeutic Strategy in Lung Cancer
- Second-Generation Inhibitors of the VEGF Receptor Tyrosine Kinase: Ongoing Studies
- Harnessing SPARC Protein for Enhanced Selective Uptake of Chemotherapy Agents in Tumors
- Targeting the RAF/MEK Pathway in Melanoma and Other Malignancies
- Understanding the Kinome and Its Role in Cancer Pathogenesis
|
|
|
Eighth International Lung Cancer Congress
- Targeting Angiogenesis in First- and Second-line Therapy of Lung Cancer
- Staging
- New Targeted Approaches to Second- and Third-line Therapy of NSCLC
- Screening
- EGFR-Targeted Therapies
- Treatment of Stage III NSCLC
- Treatment of Early-Stage NSCLC
- Personalized Approaches to the Treatment of Lung Cancer
- Cooperative Group Strategies: Roundtable Discussion on First- and Second-line Therapies of Advanced NSCLC and Limited and Extensive SCLC
- Special Populations
- SCLC and Mesothelioma
|
|
|
The Future of Lung Cancer Module
- Small-Molecule Inhibitors of VEGFR Signaling in NSCLC
- Targeted Therapy Against VEGF/VEGFR in NSCLC
- Combined EGFR and VEGF Signaling Inhibition in NSCLC
|
|
|
|
| |
PUBLICATIONS
|
 |
Vol. 7, No. 4
1 AMA
PRA Category 1 Credit™
Expiration date: January 17, 2009
- Newly Diagnosed, Advanced-Stage Non–Small-Cell Lung Cancer: Considerations for First-line Treatment
- Second- and Third-line Treatment Options for Advanced Non–Small-Cell Lung Cancer
- Agents Targeting Mammalian Target of Rapamycin and Heat Shock Protein 90 in Non–Small-Cell Lung Cancer
|
|
 |
Vol. 4, No. 10
1 AMA
PRA Category 1 Credit™
Expiration date: December 22, 2008
- Q&A: Impact of Patient and Tumor Characteristics in Lung Adenocarcinoma
- SB 1: Second-Line Therapy for Advanced NSCLC
- SB 2: Impact of Smoking History on Therapy With EGFR TKIs in Lung Cancer
|
|
 |
Vol. 8, No. 8
1 AMA
PRA Category 1 Credit™
Expiration date: December 7, 2007
- Targeted Agents in Non–Small-Cell Lung Cancer: Novel Agents, Novel Settings
- Phase III Trial of First-line Gemcitabine/Cisplatin/Bevacizumab in Advanced Nonsquamous NSCLC
- Phase III Trial of Gefitinib Compared to Docetaxel in Patients With Previously Treated Advanced NSCLC
- Phase II Trial of First-line Erlotinib in Patients With Advanced or Metastatic NSCLC
- Phase II Trial of First-line XL647 in Patients With NSCLC Enriched for Sensitivity to EGFR TKI
- Ongoing Phase II/III Trials of Antiangiogenic Agents in NSCLC
|
|
 |
December 2007
1 AMA
PRA Category 1 Credit™
Expiration date: December 7, 2008
- Molecular Pathogenesis of Non–Small-Cell Lung Cancer
- Individualizing Therapies in Non–Small-Cell Lung Cancer
Based on Tumor Biology and Patient Characteristics
- Optimizing the Use of EGFR Inhibitors in Patients With
Non–Small-Cell Lung Cancer
- Integration of Antiangiogenic Agents Into Treatment Paradigms
for Non–Small-Cell Lung Cancer
- Quality of Life and Adverse Events Associated With Targeted
Therapy in Non–Small-Cell Lung Cancer
- New Therapeutic Agents for Non–Small-Cell Lung Cancer
|
|
 |
November 2007
1 AMA
PRA Category 1 Credit™
Expiration date: November 30, 2008
- Targeting Angiogenesis in NSCLC
- Novel High-Affinity VEGF/Multitargeted TKIs
- EGFR TKIs in NSCLC
- Overcoming Resistance to EGFR TKIs
|
|
 |
Vol. 7, No. 3
1 AMA PRA Category
1 Credit™
Expiration date: November 20, 2008
- Response to TKIs Targeting EGFR
- Second-Generation EGFR TKIs
|
|
 |
November 2007
1 AMA
PRA Category 1 Credit™
Expiration date: November 20, 2008
- Targeting Signaling Pathways to Inhibit Cancer Growth
- Targeting the MAP/MEK and PI3K/Akt Pathways
- Novel Small-Molecular Inhibitors Targeting VEGFR in Breast Cancer
- Vaccines in Lung Cancer
- Novel Immunologic Targets in Metastatic Melanoma
- Combining Targeted Agents to Improve Therapeutic Efficacy
|
|
 |
November 2007
1 AMA
PRA Category 1 Credit™
Expiration date: November 20, 2008
- Combining VEGF and EGFR Inhibition in NSCLC
- Second-Generation Inhibitors of the VEGFR Tyrosine Kinase
- Small-Molecule TKIs in the Treatment of Advanced Thyroid Cancer
- Harnessing SPARC Protein for Uptake of Chemotherapy in Tumors
- Current Data on Raf/MEK Inhibitors in Melanoma and Other Cancers
- Understanding the Kinome and Its Role in Cancer Pathogenesis
|
|
 |
October 2007
1 AMA PRA Category
1 Credit™
Expiration date: October 31, 2008
- Efficacy of Biologic Targeted Agents in Hepatocellular Carcinoma
- Antiangiogenic Agents in NSCLC
- Beyond Proof of Principle for Multikinase Inhibitors in Renal Cell Carcinoma
- Update on Therapeutic Inhibition of Raf in Metastatic Melanoma
|
|
 |
Vol. 5, No. 7
0.5 AMA PRA Category
1 Credit™
Expiration date: October 22, 2008
- Advances in Chemotherapy for Metastatic NSCLC
|
|
 |
Vol. 4, No. 6
1 AMA PRA Category
1 Credit™
Expiration date: October 15, 2008
- Treatment of a Patient With Metastatic Adenocarcinoma of the Lung
|
|
 |
Vol. 8, No. 6
1 AMA PRA Category
1 Credit™
Expiration date: September 30, 2008
- Optimizing the Application of Targeted Agents in Non–Small-Cell Lung Cancer
|
|
 |
February 2007 Vol. 8, Suppl. 2
1.5 AMA PRA Category
1 Credits™
Expiration date: February 29, 2008
- Second-Generation Tyrosine Kinase Inhibitors in NSCLC
- Signaling Pathways in Lung Cancer
- EGFR Inhibitors and Chemotherapy in NSCLC
- Antiangiogenic Agents in Combination Therapy
- VEGFR Inhibitors in Lung Cancer
- VEGF and EGFR Pathways in NSCLC
|
|
